Stock Events

Stock Events

Kymera Therapeutics 

$80.16
22
-$4.02-4.78% Tuesday 04:00

Statistics

Day High
80.16
Day Low
80.16
52W High
-
52W Low
-
Volume
28
Avg. Volume
-
Mkt Cap
6.54B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Q4 2025
Next
-0.97
-0.9
-0.84
-0.77
Expected EPS
-0.880522
Actual EPS
N/A

Financials

-794.04%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
78.42MRevenue
-622.7MNet Income

Analyst Ratings

$119.11Average Price Target
The highest estimate is 140.00.
From 20 ratings within the last 6 months. This is not an investment recommendation.
Buy
95%
Hold
5%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KYMR.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, including a focus on protein degradation, which competes with Kymera's targeted protein degradation platform.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company that has been expanding its research in targeted protein degradation, directly competing with Kymera's core research focus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has been investing in the development of novel therapeutics, including those in the protein degradation space, making it a competitor to Kymera.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a broad focus on innovative therapeutics, including research into protein degradation mechanisms, positioning it as a competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has shown interest in targeted protein degradation, competing with Kymera in the quest to develop novel treatments for diseases.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has initiatives in novel therapeutic areas, including protein degradation, which aligns with Kymera's research interests.
Merck
MRK
Mkt Cap214.76B
Merck is engaged in drug discovery and development, including areas that overlap with Kymera's focus on protein degradation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse research portfolio that includes work on protein degradation, making it a competitor in the space.
Rogers
ROG
Mkt Cap1.57B
Roche, through its Genentech arm, is involved in research that competes with Kymera, including the development of treatments based on protein degradation.

About

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Show more...
CEO
ISIN
US5015751044

Listings

XNAS
US
KYMR
BOATS
BOATS
KYMR.BOATS

0 Comments

Share your thoughts

FAQ

What is Kymera Therapeutics stock price today?▼
The current price of KYMR.BOATS is $80.16 USD — it has decreased by -4.78% in the past 24 hours. Watch Kymera Therapeutics stock price performance more closely on the chart.
What is Kymera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kymera Therapeutics stocks are traded under the ticker KYMR.BOATS.
What is Kymera Therapeutics market cap?▼
Today Kymera Therapeutics has the market capitalization of 6.54B
When is the next Kymera Therapeutics earnings date?▼
Kymera Therapeutics is going to release the next earnings report on April 30, 2026.
What were Kymera Therapeutics earnings last quarter?▼
KYMR.BOATS earnings for the last quarter are -0.97 USD per share, whereas the estimation was -0.78 USD resulting in a -23.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kymera Therapeutics revenue for the last year?▼
Kymera Therapeutics revenue for the last year amounts to 78.42M USD.
What is Kymera Therapeutics net income for the last year?▼
KYMR.BOATS net income for the last year is -622.7M USD.
When did Kymera Therapeutics complete a stock split?▼
Kymera Therapeutics has not had any recent stock splits.